Oxford BioTherapeutics announced this week that Sanofi-Aventis has acquired an exclusive worldwide license to one of OBT's preclinical antibody programs.

According to a statement released by OBT, Sanofi-Aventis intends to use the antibody – which is directed against a proprietary target identified by OBT – to develop and commercialize antibody drug conjugate therapies for cancer treatment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.